Amphetamine-type substances are frequently detected among drivers injured or killed due to road-trauma. However, the role of this substance in crash causation remains equivocal. We performed a systematic review to evaluate existing evidence regarding the association between amphetamine use and the risk of injury or death due to road traffic accidents. A bibliographical search of PubMed, SafetyLit, Scopus, and Science Direct literature databases from 01 January 1980 until May 2015 was performed. The quality of included studies was assessed using the Newcastle-Ottowa Scale (NOS) (cut-off of ≥7 indicated high quality). Inter-rater reliability between three independent reviewers for the NOS was calculated using Cohens kappa (κ) statistic, and best-evidence synthesis was performed. A total of 182 articles were found. Nine studies met eligibility criteria for inclusion for review, and seven studies were included for best-evidence synthesis. Best-evidence synthesis demonstrated a conflicting level of evidence for associations between the use of-amphetamine-type substances and the risk of sustaining an injury, and a moderate level of evidence between amphetamine use and the risk of death due to road trauma. This is the first review to synthesise evidence regarding the association between amphetamine-type substance use and the risk of injury or death due to a road traffic accident. More conclusive evidence of death due to road trauma among amphetamine users may reflect significant and global deficits in functioning associated with effective vehicular control under the influence of this substance. Additional high quality, sufficiently powered studies are required to elucidate the magnitude of these associations.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.euroneuro.2016.02.012 | DOI Listing |
J Adolesc Health
February 2025
World Health Organization, Geneva, Switzerland.
J Agromedicine
January 2025
Injury Prevention and Community Outreach, University of Iowa Health Care Stead Family Children's Hospital, University of Iowa, Iowa City, IA, USA.
Most deaths due to all-terrain vehicles (ATVs) and utility task vehicles (UTVs) occur on public roads, despite manufacturers' warnings that they are not designed for roadway use. Our study objective was to determine rural residents' use, knowledge, and attitudes regarding ATVs/UTVs on public roads. A convenience sample of 2022 Farm Progress Show attendees were surveyed ( = 361).
View Article and Find Full Text PDFHeliyon
July 2024
The Design School, Taylor's University, Subang Jaya, Selangor, Malaysia.
Road traffic injuries are one of the main causes of death among children. In recent years, the incidence and casualty rates of traffic accidents have increased year by year, which is a major challenge faced by safety organizations and governments in various countries, especially in developing countries. Among them, correct understanding of road traffic signs is a factor in reducing accidents.
View Article and Find Full Text PDFJpn J Clin Oncol
January 2025
Kindai University Hospital, 377-2 Onohigashi, Osakasayama, 589-8511, Osaka, Japan.
Background: The phase 3 open-label KEYNOTE-426 study demonstrated that first-line pembrolizumab plus axitinib improved overall survival (OS) and progression-free survival (PFS) versus sunitinib for metastatic renal cell carcinoma (mRCC) in a global population. This subgroup analysis investigated the efficacy and safety of pembrolizumab-axitinib versus sunitinib in patients enrolled in KEYNOTE-426 in East Asia (Japan, South Korea, and Taiwan).
Methods: Adults with clear cell mRCC were randomly assigned 1:1 to receive intravenous pembrolizumab 200 mg every 3 weeks with oral axitinib 5 mg twice daily or oral sunitinib 50 mg once daily (4 weeks on/2 weeks off).
J Transl Med
January 2025
Department of Pathology, Renmin Hospital of Wuhan University, 238 Jiefang-Road, Wuchang District, Wuhan, 430060, P. R. China.
With breast cancer being the most common tumor among women in the world today, it is also the leading cause of cancer-related deaths. Standard treatments include chemotherapy, surgery, endocrine therapy, and targeted therapy. However, the heterogeneity, drug resistance, and poor prognosis of breast cancer highlight an urgent need for further exploration of its underlying mechanisms.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!